EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

An Open‐Label, Single‐Arm, Phase II Trial of Sintilimab Plus Anlotinib for Metastatic Non‐Small Cell Lung Cancer After First‐Line PD ‐(L)1 Inhibitor

Xun Shi, Chen Lin, Lishu Lou, Qiong He, Guangyuan Lou, Wei Hong iD, Lan Shao, Jun Zhao, Cuiping Gu, Xinmin Yu, Ying Jin iD

Cancer Medicine · 2025

DOI: 10.1002/cam4.71191 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer Medicine, 2025. Verfasst von Xun Shi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Indoles, Quinolines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zhejiang Provincial Natural Science Foundation of China, The Medical and Health Research Project of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although immune checkpoint inhibitors (ICIs) have markedly improved first‐line management of non‐small cell lung cancer (NSCLC), many tumors eventually escape control after anti‐PD‐(L)1 therapy, leaving a clear therapeutic gap. Preclinical studies and preliminary clinical data suggest that coupling ICIs with anti‐angiogenesis therapy can yield complementary antitumor effects. Consequently, we launched this investigation to evaluate the therapeutic benefit and tolerability of sintilimab, a PD‐(L)1–blocking monoclonal antibody, together with the oral multi‐target anti‐angiogenesis agent anlotinib in metastatic NSCLC individuals experiencing progression after first‐line PD‐(L)1 inhibition.

Methods

At Zhejiang Cancer Hospital, we conducted a phase II trial, single‐arm, open‐label investigation (registration No. NCT04691388). Patients were adults diagnosed with metastatic NSCLC whose disease had advanced after PD‐(L)1 blockade; they received sintilimab plus anlotinib on a 21‐day cycle. Investigator‐assessed objective response rate (ORR) served as the principal efficacy endpoint.

Results

Between March 2021 and January 2024, twenty‐nine individuals were recruited (median age 63, range 45–74, 96.6% male). Tumor assessment identified five partial responses (PR) (17.2%), nineteen cases of stable disease (SD) (65.5%) and three progressions (10.3%), yielding an ORR of 17.2% and a disease‐control rate (DCR) of 82.8%. The cohort's median progression‐free survival (PFS) measured 5.0 months (90% CI, 4.2–7.3), and 41.1% of participants remained progression‐free at six months. Overall survival reached a median of 15.1 months (90% CI, 8.6–not yet reached), with an 18‐month survival proportion of 44.8%. Grade ≥ 3 treatment‐related toxicity was dominated by hypertension, occurring in 10.3% of participants; no patient discontinued therapy or died because of drug‐related events.

Conclusion

Sintilimab combined with anlotinib exhibited favorable antitumor activity and tolerable toxicity in post‐anti‐PD‐(L)1 therapy of metastatic NSCLC patients, supporting further randomized controlled trials. Trial Registration ClinicalTrials.gov : NCT04691388. Registered December 31, 2020

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsIndolesQuinolinesAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsImmune Checkpoint InhibitorsHumansMaleFemaleMiddle AgedAgedB7-H1 AntigenAdult

Stichwörter der Autor:innen

anti‐angiogenic therapycombinationimmunotherapynon‐small‐cell lung cancerpreviously treated

Substanzen

anlotinibIndolesQuinolinesAntibodies, Monoclonal, HumanizedsintilimabB7-H1 AntigenCD274 protein, humanImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.

ORCID-Profile: Wei Hong, Ying Jin

Förderung

  • Zhejiang Provincial Natural Science Foundation of China
  • The Medical and Health Research Project of Zhejiang Province

Zitieren

APA

Shi, X., Lin, C., Lou, L., He, Q., Lou, G., Hong, W., Shao, L., Zhao, J., Gu, C., Yu, X., & Jin, Y. (2025). An Open‐Label, Single‐Arm, Phase II Trial of Sintilimab Plus Anlotinib for Metastatic Non‐Small Cell Lung Cancer After First‐Line PD ‐(L)1 Inhibitor. Cancer Medicine. https://doi.org/10.1002/cam4.71191

Vancouver

Shi X, Lin C, Lou L, He Q, Lou G, Hong W, et al. An Open‐Label, Single‐Arm, Phase II Trial of Sintilimab Plus Anlotinib for Metastatic Non‐Small Cell Lung Cancer After First‐Line PD ‐(L)1 Inhibitor. Cancer Medicine. 2025. doi:10.1002/cam4.71191

BibTeX
@article{Shi2025,
  author = {Shi, Xun and Lin, Chen and Lou, Lishu and He, Qiong and Lou, Guangyuan and Hong, Wei and Shao, Lan and Zhao, Jun and Gu, Cuiping and Yu, Xinmin and Jin, Ying},
  title = {An Open‐Label, Single‐Arm, Phase II Trial of Sintilimab Plus Anlotinib for Metastatic Non‐Small Cell Lung Cancer After First‐Line PD ‐(L)1 Inhibitor},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71191}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche